Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Firategrast dose-ranging study in relapsing-remitting multiple sclerosis
2006-002633-20Phase 2Completed
- Sponsor
- GSK
- Start
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of firategrast in relapsing-remitting multiple sclerosis (RRMS) (7 arms), sponsored by GSK. Primary endpoint: Cumulative number of new gadolinium-enhancing lesions. Started Aug 2006; status: completed.
02
Drugs
firategrast
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2006-002633-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002633-20.